HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

An association between infantile haemangiomas and erythropoietin treatment in preterm infants.

AbstractBACKGROUND:
Infantile haemangiomas are benign vascular neoplasms that occur frequently in premature infants. The authors hypothesised that in addition to gestational age and birth weight, erythropoietin therapy may influence the incidence of these soft tissue tumours in preterm infants.
METHODS:
2563 infants born prematurely and admitted to the Division of Neonatology, University of Heidelberg Medical School were investigated in a retrospective analysis. Hospital charts for all infants were reviewed for clinical data. The primary endpoint was the percentage of infants who had received erythropoietin treatment and were diagnosed with a haemangioma.
RESULTS:
Haemangiomas were diagnosed in 4.3% (n=110) of the 2563 preterm infants. These 110 infants had a median gestational age of 29 weeks (IQR 27-33 weeks) and the female:male ratio was 1.8:1. A higher incidence of haemangiomas (12-15%) was detected in premature infants with a lower gestational age (<31 weeks). Erythropoietin therapy was shown to be an independent risk factor after adjusting for all other known factors and oxygen therapy in multivariable analysis (HR 2.82, 95% CI 1.55 to 5.12). Subgroup analysis revealed that the effect was more pronounced in male than female infants (HR 3.61, 95% CI 1.52 to 8.57).
CONCLUSIONS:
This retrospective study demonstrates that erythropoietin treatment is associated with an increase in the incidence of these benign vascular tumours after adjusting for all other factors.
AuthorsCorinna Doege, Maria Pritsch, Michael C Frühwald, Jacqueline Bauer
JournalArchives of disease in childhood. Fetal and neonatal edition (Arch Dis Child Fetal Neonatal Ed) Vol. 97 Issue 1 Pg. F45-9 (Jan 2012) ISSN: 1468-2052 [Electronic] England
PMID21546402 (Publication Type: Journal Article)
Chemical References
  • Recombinant Proteins
  • Erythropoietin
Topics
  • Birth Weight
  • Erythropoietin (adverse effects)
  • Female
  • Germany (epidemiology)
  • Gestational Age
  • Hemangioma (chemically induced, epidemiology)
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Infant, Premature, Diseases (chemically induced, epidemiology)
  • Male
  • Prevalence
  • Recombinant Proteins (adverse effects)
  • Retrospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: